Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Medically reviewed by Doru Paul, MD Key Takeaways Low platelets can occur when your bone marrow doesn't make enough platelets ...

Please provide your email address to receive an email when new articles are posted on . Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, ...

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of ...